EÖTVÖS LORÁND UNIVERSITY (ELTE), FACULTY OF SCIENCE First-in-class antispastic drug candidate to reach clinical phase is published in the prestigious life science journal, Cell. Drug candidate MPH-220 could mean new hope for millions of patients suffering from spasticity. Chronic muscle spasticity after nervous system defects like stroke, traumatic brain and spinal cord injury, multiple sclerosis and painful...
Tag: <span>muscle spasticity</span>
Post
Progressive Supranuclear Palsy (PSP) Versus Parkinson’s Disease
Progressive supranuclear palsy (PSP) is a rare brain disorder that affects approximately 6 in 100,000 people worldwide. It causes muscle weakness and affects gait, balance and overall movement, as well as the patient’s mood, cognitive skills and behavior. While no treatment is available at this time, various symptoms can be managed with the use of medication or other...